REPL daily stock chart from Finviz. The image is loaded as a static chart; the click opens the Finviz quote page.

Nasdaq: $REPL · Biotech · Oncolytic Immunotherapy

Replimune Group Stock Hub: RP1, the FDA Resubmission and the Last Chance for an Oncolytic Melanoma Story

A complete updated hub on Replimune, RP1, the two FDA complete response letters, the June 2026 BLA resubmission acceptance, the late-July advisory committee risk, the August 2, 2026 action date, the latest fiscal-year results, and what this final regulatory window means for the company.

Updated: July 1, 2026 Primary catalyst: FDA RP1 action date FDA goal date: August 2, 2026 AdCom expected: late July 2026 Educational content only

Executive Summary

Replimune is now one of the cleanest examples of what biotech traders call a true binary name: not because the story is simple, but because the next FDA decision could redraw the whole company. The stock is no longer only about a clinical dataset, a pipeline platform, or a long-term cancer-immunotherapy thesis. It is about whether the FDA is willing to grant accelerated approval to RP1 after two previous complete response letters that questioned whether the evidence package was adequate, well-controlled, and interpretable.

RP1 is Replimune’s lead product candidate. It is an oncolytic immunotherapy built on a genetically modified herpes simplex virus type 1 backbone. The idea is direct and ambitious: inject the virus into tumors, drive local tumor killing, release tumor antigens, alter the tumor microenvironment, and generate a broader immune response that can work together with checkpoint blockade. In the current BLA, RP1 is being evaluated in combination with nivolumab for advanced melanoma patients who have progressed after prior anti-PD-1-based therapy.

The clinical story is compelling enough to keep specialists, patients, and investors engaged. Replimune has reported a response rate around one-third of treated anti-PD-1-failed melanoma patients, durable responses, a median duration of response of 24.8 months, median overall survival of 32.9 months in a three-year landmark analysis, and a 47.8% three-year overall survival rate in the full treated population. Among responders, the reported three-year overall survival rate was 83.5%. Those numbers are the reason the asset still has a story after two CRLs.

But the regulatory problem is just as real. The FDA’s April 2026 complete response letter, now publicly available through FDA’s CRL database, repeated core objections that go back to the initial July 2025 rejection: the pivotal IGNYTE dataset was single-arm, the trial was not considered adequate and well-controlled, the patient population was heterogeneous, response assessment issues created interpretability concerns, and the study did not isolate the contribution of RP1 when used with nivolumab. The FDA also said the early randomized data submitted from the ongoing Phase 3 confirmatory study represented only 10% of planned enrollment and did not solve the evidentiary problem.

That is why the June 2026 acceptance matters so much. Replimune announced on May 29, 2026 that it had aligned with the FDA on a path forward for resubmission and that FDA would treat the new filing as an urgent matter. On June 26, 2026, the company announced the FDA had accepted the RP1 BLA resubmission as a complete Class 1 response, with a goal date of August 2, 2026 and an advisory committee expected in late July. This moved the stock from a post-CRL damage story back into a live FDA catalyst story.

The latest fiscal-year results sharpen the setup. As of March 31, 2026, Replimune reported $268.9 million in cash, cash equivalents and short-term investments, down from $483.8 million one year earlier. The company guided that existing cash should fund operations into the first quarter of calendar 2027, including scale-up for potential RP1 commercialization in skin cancers and general corporate purposes, excluding any potential revenue. That is enough runway to reach the August FDA decision, but it is not enough to remove financing risk if approval is delayed, rejected, or tied to heavy post-marketing obligations.

The most important interpretation is simple: this latest FDA opening is not just another shot at a label. It is effectively a referendum on RP1’s near-term viability in advanced melanoma. Replimune itself said after the April CRL that, without timely accelerated approval, RP1 development would not be viable. If the FDA approves, Replimune gets regulatory validation, potential first commercial revenue, a stronger financing position, and a renewed platform narrative. If the FDA says no again, the company may still own interesting science and additional programs, but the market will likely question the cost of continuing RP1, the durability of the RPx platform thesis, and the need for restructuring, partnering, or portfolio prioritization.

Why Replimune Matters Now

Replimune matters now because the company sits at the intersection of four powerful biotech themes: regulatory flexibility in oncology, accelerated approval standards, the commercial future of oncolytic immunotherapy, and the capital-market consequences of a lead-asset binary event.

The FDA is not being asked to approve a low-risk incremental drug supported by a large randomized dataset with a clean survival endpoint. It is being asked to decide whether a single-arm Phase 1/2 dataset, supported by durability, survival follow-up, expert support, patient-need arguments and an ongoing confirmatory trial, is enough for accelerated approval in a population with limited options. This is the kind of decision that can become larger than one company because it touches the broader debate over how much flexibility regulators should use for serious diseases when randomized evidence is incomplete.

For Replimune, the story is even more concentrated. The company does not yet have a commercial product. RP1 is the lead asset and the central validation engine for the RPx platform. The pipeline includes RP2 and other platform extensions, but the market’s near-term confidence in the whole company is tied to whether RP1 can cross the regulatory line first. Approval would not automatically make Replimune a successful commercial oncology company, but it would change the conversation. It would move the company from “promising clinical-stage platform with regulatory damage” to “approved oncolytic immunotherapy platform with a launch challenge.”

That distinction matters. A development-stage biotech can have strong science and still struggle if the FDA does not accept the evidence package. A commercial-stage biotech can still fail if launch execution disappoints, but it has a different financing toolkit, a different strategic profile, and a different investor base. RP1 approval would give Replimune something it currently lacks: a regulatory proof point. A third rejection would do the opposite: it would force the market to ask whether the company can keep funding RP1 and the RPx platform without near-term product revenue.

Company Overview

Replimune Group is a clinical-stage biotechnology company headquartered in Woburn, Massachusetts. The company was founded in 2015 with the mission of transforming cancer treatment through oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone designed to drive immunogenic tumor-cell death, release tumor-derived antigens, and activate systemic anti-tumor immune responses.

The core scientific idea behind Replimune is that tumors can be turned into immune-activating sites. Instead of treating cancer only as a target to be attacked from the outside, the RPx approach tries to use the tumor itself as a source of antigens and immune stimulation. RP1 is the first major test of that concept in the public markets and in front of the FDA.

RP1 is engineered to express GM-CSF and the fusogenic protein GALV-GP R-. GM-CSF is intended to help stimulate immune responses, while the fusogenic element is designed to increase direct tumor-killing potency and immunogenicity. RP2 builds on the RP1 backbone by adding an anti-CTLA-4 antibody-like molecule, with the goal of enhancing immune activation in tumor types that may be less naturally responsive to checkpoint blockade.

As of the latest company update, the key programs are RP1 in advanced melanoma and other skin-cancer contexts, and RP2 in metastatic uveal melanoma through the REVEAL study. RP1 remains the defining asset. RP2 provides pipeline optionality, but it does not remove the near-term centrality of the August 2026 RP1 decision.

The RPx Platform in Plain English

Oncolytic immunotherapy is built around a powerful but difficult promise: use a virus to infect and kill tumor cells while also making the immune system more likely to recognize and attack cancer. The ideal result is not only local shrinkage of injected lesions, but also systemic immune activity against non-injected tumors and metastatic disease.

That last point matters for RP1. The FDA’s skepticism is not that tumor injection cannot kill injected lesions. The deeper issue is whether the clinical evidence clearly shows that RP1 contributes meaningful systemic benefit when combined with nivolumab. If responses are heavily influenced by injected-lesion manipulation, surgical procedures, assessment methodology or patient heterogeneity, the agency can question whether the observed response rate truly proves the drug’s contribution.

This is the central tension in the Replimune story. The clinical data show durable responses and long survival in a difficult melanoma setting. The regulatory critique asks whether those outcomes can be confidently attributed to RP1 in a way that meets statutory evidentiary standards. Investors can admire the biology and still respect the FDA’s concern. Both things can be true at the same time.

RP1: The Lead Asset

RP1, also known as vusolimogene oderparepvec, is Replimune’s lead product candidate. It is an HSV-1-based oncolytic immunotherapy designed to maximize tumor killing potency, immunogenic cell death and systemic immune activation. In the BLA currently under review, RP1 is being combined with nivolumab in adult patients with advanced melanoma who have progressed after a prior anti-PD-1-containing regimen.

The indication matters because post-PD-1 advanced melanoma is a high-need setting. Checkpoint inhibitors changed the melanoma treatment landscape, but not every patient responds, and many patients eventually progress. Replimune’s argument is that RP1 plus nivolumab can deliver meaningful and durable benefit in patients who have already failed prior anti-PD-1 therapy.

The clinical support for the BLA is based primarily on the IGNYTE clinical trial. The company’s public materials describe a cohort of 140 advanced melanoma patients with confirmed progression on anti-PD-1 therapy. The key reported efficacy signals include an objective response rate of 33.6% by RECIST 1.1, a median duration of response of 24.8 months, and a favorable safety profile with no new safety signals in the three-year update.

Those numbers are not trivial. In oncology, a durable response in a refractory population can be clinically meaningful even if the trial is not perfect. That is the bull argument. The bear argument is that accelerated approval still requires evidence strong enough for regulators to conclude that the drug is reasonably likely to predict clinical benefit, and the FDA has already twice argued that Replimune’s evidence package did not cross that bar.

The Clinical Evidence: What Supports the Bull Case

The strongest clinical argument for RP1 is durability. The company’s ASCO 2026 update reported median overall survival of 32.9 months in the IGNYTE melanoma cohort, a three-year overall survival rate of 47.8% in all treated patients, and an 83.5% three-year overall survival rate among responders. Median duration of response was 24.8 months, and the company said no new safety signals were observed.

For a patient population that has already progressed on anti-PD-1 therapy, that durability is the reason this story did not disappear after the first CRL. A short-lived response rate in an uncontrolled study would be easier for regulators and investors to discount. Durable responses, survival follow-up and strong clinician support create a more complex discussion. They do not guarantee approval, but they keep the benefit-risk debate alive.

Replimune has also emphasized a favorable safety profile. In the July 2025 CRL announcement, the company said the FDA did not raise safety issues. In the April 2026 CRL announcement, the company again framed the disagreement as one about sufficiency and interpretation of the dataset rather than a primary safety problem. The April 2026 company statement reported a 34% response rate, a median duration of response of 24.8 months and a favorable safety profile in patients with confirmed progression after anti-PD-1-based therapy.

That distinction matters for the advisory committee. If the FDA discussion were mainly about a severe safety signal, the calculus would be different. Here, the likely debate is about benefit evidence, trial design, contribution of components, accelerated approval flexibility and unmet medical need. That does not make the decision easy, but it defines the battlefield.

The FDA Problem: Why Two CRLs Happened

The FDA problem is not mysterious anymore. The April 2026 complete response letter is public and unusually useful for understanding the dispute. The agency said that the data presented were insufficient to conclude substantial evidence of effectiveness for vusolimogene oderparepvec in unresectable advanced cutaneous melanoma. It identified deficiencies in the single-arm RPL-001-16 / IGNYTE dataset and in the limited randomized RP1-104 / IGNYTE-3 data submitted with the first resubmission.

For RPL-001-16, the FDA highlighted inability to isolate the contribution of RP1 when administered with nivolumab, heterogeneity of the study population, and uncertainty around response assessments, including surgical interventions with potential to confound response results. For RP1-104, the FDA highlighted the limited number of patients treated to date, investigator-only response assessment, lack of duration-of-response data, and difficulty interpreting progression-free survival due to lack of pre-specification and type-1 error control.

The FDA also made clear that it had communicated concerns about the study design in prior interactions. In the April 2026 letter, the agency referred back to a March 2021 Type B meeting in which it said the proposed single-arm study would not enable identification of the contribution of each component of the combination and recommended a randomized controlled trial to demonstrate efficacy, safety and contribution of components. The agency also noted it had concerns about baseline heterogeneity and response interpretation in injected lesions.

This matters because the bear case is not simply “FDA was arbitrary.” Replimune argues the process was inconsistent and that the company had prior alignment on the submission path. The FDA argues that the core study-design concerns were communicated repeatedly and remained unresolved. The advisory committee will likely need to wrestle with both the clinical reality of patient need and the regulatory reality of evidentiary standards.

Regulatory Timeline: From Breakthrough Designation to the Third FDA Opening

Replimune’s regulatory path is the heart of this stock hub. It is important to read it sequentially because each step changed the narrative.

What the Latest FDA Resubmission Really Means

The June 2026 acceptance does not mean RP1 is approved. It also does not mean the FDA has reversed its scientific concerns. It means the FDA has accepted Replimune’s latest response for review, classified it as a complete Class 1 response, set a short goal date, and indicated that an advisory committee should be expected.

That classification matters. A Class 1 review is shorter than the Class II timeline used for the October 2025 resubmission. In practical market terms, the timeline is compressed. Traders do not have a distant PDUFA many quarters away. They have a late-July AdCom window and an August 2 decision date. That is exactly the type of setup that can create sharp pre-event speculation, violent position unwinds, and exaggerated moves on briefing documents, AdCom votes, label commentary or FDA leaks.

From a company perspective, the acceptance gives Replimune a chance to argue the case publicly and scientifically. The expected AdCom may be a risk, but it is also an opportunity. If panel members focus on unmet need, durability, safety and patient access, the tone could support the bull case. If they focus on trial design, contribution of components and the precedent of approving based on an uncontrolled dataset after two CRLs, the tone could support the bear case.

The key point is that this is not merely a paperwork event. It is the difference between RP1 remaining a potentially approvable asset under accelerated approval and RP1 being forced back into a longer, more expensive, randomized-evidence path that the company has already described as economically difficult.

Why This Is Replimune’s Last Chance — and What “Last Chance” Actually Means

Calling this the “last chance” does not mean Replimune legally cannot ever run another trial or submit another application. Biotech development can continue for years if capital, partners and patient enrollment are available. But in practical public-market terms, this is the last near-term accelerated-approval window for RP1 in advanced melanoma based primarily on the current IGNYTE package plus supporting analyses and ongoing confirmatory-trial context.

There are five reasons this matters.

1. RP1’s near-term melanoma viability is tied to accelerated approval

Replimune’s own language after the April 2026 CRL was unusually direct: without timely accelerated approval, development of RP1 would not be viable. That sentence is central. It tells investors that the company is not treating another CRL as a minor delay. It is treating it as a strategic threat to the lead program.

The reason is cost. Continuing a randomized, global, confirmatory path without near-term approval can require substantial capital, manufacturing expense, clinical operations and time. For a company with no product revenue and cash runway into Q1 2027, a long delay would likely force difficult choices.

2. The commercial infrastructure decision depends on approval

Replimune had been preparing for potential RP1 commercialization. The latest fiscal-year update explicitly says cash runway includes scale-up for potential commercialization of RP1 in skin cancers. That means approval unlocks a launch path. Another rejection makes that infrastructure harder to justify and may push management toward restructuring, partnering, cost reduction or a smaller clinical footprint.

3. The RPx platform needs a first regulatory validation

RP1 is not only one product candidate. It is the first major regulatory test of Replimune’s platform. RP2 and other extensions may have their own biology and their own clinical paths, but investors will naturally use RP1 as a proxy for whether the platform can produce approvable oncology products. Approval would validate more than a melanoma label. Another CRL would raise the bar for believing that platform promise can translate into regulatory success.

4. The balance sheet clock is running

The company ended fiscal 2026 with $268.9 million in cash, cash equivalents and short-term investments, compared with $483.8 million one year earlier. The annual net loss was $313.9 million. Cash runway into Q1 2027 is meaningful, but not open-ended. An approval would improve the company’s strategic options. A rejection would likely make future financing more dilutive, more difficult, or more dependent on portfolio cuts and partnering.

5. The market has already repriced the story as a binary

The stock has already moved from deep post-CRL distress to a much higher valuation after the third FDA opening. That means some optimism is already embedded. The upside case may still be large if FDA approval arrives, but the downside risk is also large because investors who bought the “FDA reconsideration” narrative could exit quickly if advisory committee documents or votes turn negative.

Latest Fiscal-Year Results: Cash, Burn and Runway

Replimune reported fiscal fourth quarter and fiscal year 2026 results on June 29, 2026. The numbers are important because they show that the company has enough cash to reach the FDA decision, but not enough financial room to absorb indefinite delay without major strategic consequences.

The financial profile is not immediately distressed, but it is not comfortable either. The company can reach the catalyst. It can prepare for a potential launch. It can continue key programs in the near term. But if RP1 is not approved, the runway will become a strategic constraint, not just a financial metric.

That is why the August decision is so important. Approval does not eliminate dilution risk. In fact, commercialization can require more capital. But approval gives a company more ways to raise, partner, borrow or sequence spending. A third CRL reduces leverage. It makes every dollar more defensive and every financing conversation more difficult.

Pipeline and Program Map

Replimune is often discussed as if it were only RP1. In the near term, that is understandable because the FDA decision dominates the story. But for a full stock hub, the pipeline matters because it frames what remains if RP1 succeeds, and what could still exist if RP1 fails.

Competitive Context: Where RP1 Fits

Advanced melanoma is not an empty therapeutic field. Checkpoint blockade has already transformed outcomes for many patients. Cellular therapy and other immunotherapy approaches have also changed the discussion. That makes RP1’s position nuanced. It is not trying to replace first-line checkpoint inhibitors. It is trying to offer a new option after anti-PD-1 failure, where treatment choices remain limited and outcomes are still poor for many patients.

The strongest commercial argument is that an approved RP1 could occupy a meaningful niche if physicians see durable benefit, manageable safety and a practical treatment workflow. The challenge is that intratumoral therapy is operationally different from a simple systemic infusion. It requires appropriate lesions, procedural capability, comfort with injection logistics and clear physician confidence that the benefit justifies the treatment process.

The FDA decision would not answer all commercial questions. Approval would validate the regulatory path, but launch execution would still matter. Reimbursement, treatment-center adoption, physician education, patient selection and competition from other melanoma approaches would determine how much revenue RP1 can actually generate.

Advisory Committee Watch: What to Look For

The expected late-July advisory committee is the next major information event before the August 2 FDA goal date. AdComs can be noisy, but they often define the tone of the final decision. For REPL, the panel discussion may matter as much as the vote.

Key questions for the panel

• Is the response durability clinically meaningful enough to support accelerated approval in this high-unmet-need population?
• Can the contribution of RP1 be reasonably inferred when RP1 is used with nivolumab in a single-arm dataset?
• Do response assessment issues materially weaken the dataset, especially around injected lesions, non-injected lesions, surgical procedures and RECIST methodology?
• Does the ongoing IGNYTE-3 trial provide enough confirmatory reassurance even if randomized evidence remains immature?
• Would approval create an unacceptable precedent for single-arm oncology applications, or is this exactly the kind of high-need case where accelerated approval flexibility exists?
• What label, post-marketing requirements or restrictions would be necessary if approval is granted?

Possible AdCom tones

Capital Structure and Dilution Risk

Replimune’s capital structure cannot be analyzed only by looking at cash on the balance sheet. In development-stage biotech, the question is always how much cash remains, how fast the company is burning, what event comes next, and whether the next financing happens from strength or weakness.

At March 31, 2026, the company had $268.9 million in cash, cash equivalents and short-term investments. That is enough to avoid immediate financing panic before the August 2026 decision. The issue is what happens after the decision. If RP1 is approved, launch preparation and commercialization may require additional capital, but the company would likely have better strategic leverage. If RP1 is rejected, the same cash balance becomes a countdown clock for restructuring decisions.

The annual loss also matters. Replimune’s net loss widened to $313.9 million in fiscal 2026. R&D expense rose to $221.2 million and SG&A rose to $98.7 million. A company spending at that level cannot casually absorb another multi-year regulatory delay without changing something. That “something” could be reduced spending, layoffs, manufacturing scale-back, portfolio prioritization, partnership discussions, equity financing, debt restructuring or a combination of these.

For traders, the practical lesson is clear: approval can reduce financing pressure but may not eliminate dilution; rejection can increase dilution risk and make any financing more painful.

Management and Execution Risk

Sushil Patel, Ph.D., CEO of Replimune, has taken a forceful public position after the second CRL. The April 2026 company statement was not a soft biotech setback press release. It directly challenged the FDA’s process, argued that the agency had not exercised regulatory flexibility, and said the company had no choice but to eliminate jobs and substantially scale back U.S. manufacturing operations without timely accelerated approval.

This creates a two-sided management read. On one hand, the company fought aggressively for the asset, mobilized support, re-engaged with the FDA, and secured a third review window that many investors did not expect after the second CRL. That is a positive execution point. On the other hand, the company reached a position where its lead asset had already received two CRLs, and the FDA’s publicly released letter says the agency had communicated study-design concerns going back years. That raises fair questions about regulatory strategy, risk management and whether management overestimated FDA flexibility.

The market does not need a moral judgment here. It needs an execution judgment. If Replimune wins approval, management’s aggressive persistence will look like a major value-preserving move. If the FDA rejects again, the same strategy may be viewed as a costly delay in accepting the need for stronger controlled evidence or a broader portfolio reset.

Analyst and Market Opinion Snapshot

Analyst data around REPL have been highly unstable because the stock moved through two CRLs and then a sudden third FDA opening. At the time of this update, public aggregator data showed a broadly cautious analyst backdrop rather than a clean bullish consensus. MarketWatch listed an average target near $8.17 with a high target of $17 and a low target of $1, while other aggregators showed similar dispersion and several rating changes after the June 2026 FDA acceptance.

This wide target range is more useful than the average. It shows that analysts are not valuing REPL as a normal earnings-growth story. They are assigning sharply different probabilities to approval, launch value, post-CRL downside, and the residual value of the RPx platform. In a binary FDA setup, the consensus target can lag the real risk because the stock may gap far beyond target assumptions in either direction once the event is resolved.

Retail Sentiment: Reddit, Stocktwits and X

Retail sentiment around REPL is naturally intense because the story has everything biotech traders react to: FDA drama, two CRLs, a surprise third opening, large percentage stock moves, a near-term AdCom, a hard PDUFA date and a survival dataset that supporters view as clinically meaningful. On Reddit, Stocktwits and X, the bullish retail narrative tends to focus on patient need, durable responses, lack of major safety objections, alleged FDA inconsistency, and the possibility that the advisory committee gives RP1 a more balanced public hearing.

The bearish retail narrative is just as visible. Skeptics focus on the fact that the FDA has already rejected the application twice, that the core dataset is single-arm, that contribution of components remains unresolved, and that the company’s runway does not give it infinite room for another delay. Some traders also argue that the stock has already priced in too much optimism after the third opening.

This sentiment is useful only as a positioning indicator. Retail comments are not clinical evidence, not regulatory evidence, and not professional investment research. They can help explain volatility, but they cannot resolve the FDA question.

Scenario Analysis

REPL should be analyzed as a set of scenarios rather than as a single forecast. The next events are binary enough that a balanced stock hub needs to map both sides clearly.

Bull Scenario: FDA Approval

In the bull scenario, the advisory committee discussion is constructive or at least not hostile, the FDA accepts that the totality of evidence supports accelerated approval, and RP1 receives approval in advanced melanoma after anti-PD-1 failure. The label may include restrictions, confirmatory requirements and post-marketing obligations, but the key point is that RP1 becomes Replimune’s first approved product.

The likely consequences would be significant. Replimune would gain regulatory validation for RP1, strengthen the RPx platform narrative, improve its financing position, and shift the investor debate toward launch execution. The company would still face commercial risk, manufacturing risk, reimbursement risk and the need to complete confirmatory obligations. But approval would dramatically change the strategic discussion from survival mode to launch mode.

Moderate Bull Scenario: Approval With Tight Conditions

A more nuanced positive scenario is approval with a cautious label, strict post-marketing obligations, limited initial commercial assumptions, and continued scrutiny of confirmatory trial progress. This would still be positive because it gives RP1 market access, but it could cap upside if investors conclude the commercial opportunity is narrower than hoped or if the confirmatory burden is expensive.

Neutral / Mixed Scenario: Delay or Information Request

A delay is possible in any FDA process, especially with an AdCom so close to the action date. A short administrative delay would be different from a substantive delay. If FDA needs more time but remains constructive, the stock may stay volatile but not necessarily break. If the delay signals unresolved evidentiary issues, the market could treat it more like a soft rejection.

Bear Scenario: Third CRL

The bear scenario is a third complete response letter. In that case, the FDA may again conclude that the current evidence does not demonstrate substantial evidence of effectiveness and that controlled data are needed. This would be a severe blow because it would follow two prior CRLs and a high-profile third opening. The stock would likely reprice around restructuring risk, pipeline residual value, cash runway, and the probability of a partner or strategic alternative.

Severe Bear Scenario: Negative AdCom Before FDA Action

The worst near-term setup would be strongly negative FDA briefing documents followed by a negative advisory committee vote. In that case, the market may begin pricing a CRL before the August 2 action date. This is why late-July documents and panel tone matter so much. The official FDA decision is the endpoint, but the AdCom can move the stock first.

Red Flags

• Two prior FDA complete response letters. The application has already failed twice, and the FDA’s April 2026 letter provides detailed reasons.
• Single-arm evidence risk. The main IGNYTE dataset lacks a concurrent control arm, which is central to FDA skepticism.
• Contribution-of-components concern. The FDA has questioned whether the data isolate RP1’s contribution when used with nivolumab.
• Response-assessment complexity. Intratumoral therapy creates special interpretability issues around injected lesions, non-injected lesions and surgical interventions.
• Limited randomized support so far. The randomized Phase 3 data submitted with the prior resubmission represented only 10% of planned enrollment according to the FDA CRL.
• Cash runway is finite. Runway into Q1 2027 is enough to reach the catalyst, but not enough to ignore future financing or restructuring risk.
• No approved commercial product yet. Replimune remains dependent on external capital and regulatory success.
• AdCom volatility. Briefing documents, panel questions and vote wording can move the stock sharply before the FDA action date.

Positive Factors

• FDA accepted the new resubmission. The BLA is alive again with a defined August 2, 2026 goal date.
• Class 1 review indicates urgency. The timeline is short and reflects a prioritized review process.
• Durable clinical signal. Replimune has reported durable responses and long-term survival data in a difficult melanoma population.
• Safety has not been the central objection. The regulatory dispute has focused mainly on evidence and interpretability, not a prohibitive safety signal.
• High unmet need. Advanced melanoma after anti-PD-1 failure remains a serious setting with limited options for many patients.
• Pipeline optionality exists. RP2 and the RPx platform provide additional long-term scientific optionality, though they do not neutralize the RP1 binary.

What to Watch Next

1. FDA advisory committee announcement and briefing documents. These will likely be the most important pre-PDUFA information release.
2. Panel vote and discussion quality. The vote matters, but the reasoning may matter even more for interpreting final FDA probability.
3. FDA language on contribution of components. Any shift here would be highly relevant.
4. FDA language on response assessment and non-injected lesions. This is one of the technical areas that can decide the debate.
5. Confirmatory trial expectations. Approval may depend on how comfortable FDA is with IGNYTE-3 status and post-marketing commitments.
6. Cash runway commentary after the decision. Approval or rejection will likely change the financing and restructuring conversation.
7. Commercial launch details if approved. Label, target population, treatment logistics, centers, reimbursement and sales buildout will become the next debate.
8. RP2 progress. REVEAL remains relevant for the longer-term platform story, especially if RP1 creates or destroys confidence in the RPx approach.

Bottom Line

Replimune is back on the FDA calendar, and that alone changes the story. After the April 2026 second CRL, RP1 looked close to being stranded outside a viable accelerated-approval path. The May 29 FDA dialogue and June 26 BLA resubmission acceptance reopened the door. The company now has a defined August 2, 2026 action date and an expected late-July advisory committee.

But this is not a clean derisking event. The same clinical strengths and regulatory weaknesses remain locked against each other. RP1 has shown durable responses, long survival follow-up and a favorable safety profile in a high-need melanoma setting. The FDA has twice said the evidence package did not meet the required standard because of study design, interpretability, contribution-of-components and limited controlled-data concerns.

That is why this is a high-intensity stock hub, not a simple bullish update. Approval could transform Replimune from a damaged clinical-stage biotech into a company with its first commercial asset and a validated platform narrative. A third CRL could force a much harder discussion about RP1 viability, cash runway, restructuring, dilution and what remains of the RPx story without near-term regulatory validation.

The cleanest summary is this: REPL is a last-chance accelerated-approval setup around RP1. The opportunity is real, the clinical signal is real, the FDA concerns are real, and the next few weeks may decide whether Replimune gets to become a commercial oncology company or must rebuild the story around a much harder path.

Related Merlintrader Coverage

Primary Sources and Reference Links

• Replimune — June 26, 2026 FDA acceptance of RP1 BLA resubmission
• Replimune — Fiscal fourth quarter and fiscal year 2026 financial results
• Replimune — May 29, 2026 planned RP1 BLA resubmission after FDA discussion
• Replimune — April 10, 2026 second Complete Response Letter announcement
• FDA — April 10, 2026 Complete Response Letter for BLA 125827
• Replimune — July 22, 2025 first Complete Response Letter announcement
• Replimune — January 21, 2025 BLA acceptance and Priority Review
• Replimune — November 21, 2024 Breakthrough Therapy designation and BLA submission
• SEC — Replimune FY 2026 Form 10-K filing detail
• Reuters — Replimune gets third FDA chance after prior setbacks
• MarketWatch — REPL analyst estimates and target snapshot